N Concordance 1 dard chemotherapy, followed by ablative chemotherapy and chest irradiation. One 2 , a comparison of conventional adjuvant chemotherapy vs high-dose chemotherapy a 3 iography is unnecessary if multi-agent chemotherapy is part of the standard app 4 e and after each cycle of anthracycline chemotherapy associated with ICRF-187 an 5 96 in children receiving antineoplastic chemotherapy or bone marrow transplantat 6 icate that this combined intra-arterial chemotherapy and radiotherapy regimen wo 7 efficacy of CMF with doxorubicin-based chemotherapy for metastatic disease and 8 nce of the patient on infusional cancer chemotherapy (ICC) is paramount to patie 9 of aggressive local therapy with CHOP chemotherapy and involved field radiatio 10 ls in which cisplatin-based combination chemotherapy was compared with supportiv 11 g an accelerated boost with concurrent chemotherapy for small cell lung cancer. 12 ent trial using high-dose consolidation chemotherapy with autologous bone marrow 13 m cell harvest. The use of conventional chemotherapy alone to purge these tumor 14 emesis induced by moderately emetogenic chemotherapy oral dexamethasone or oral 15 ucovorin rescue; and triple intrathecal chemotherapy (TIT). Following inductio 16 m progressing patients after first-line chemotherapy could allow the selection o 17 after intensive, but non-myeloablative chemotherapy with fludarabine/cyclophosp 18 sies in patients receiving neoadjuvant chemotherapy for locally advanced breast 19 y investigated the role of preoperative chemotherapy in squamous cell cancer of 20 ach used. In most cases, post-remission chemotherapy also includes drugs not use 21 ian survival since the start of salvage chemotherapy: 13.9 months (12.3 to 20.1) 22 are then randomized to receive standard chemotherapy (cyclophosphamide, methotr 23 rmonal therapy with mitotane, systemic chemotherapy, or (for localized lesions)